RNS Hotlist: All Active, Angle, Aquis, Atlantic Lithium, Condor, Capital Metals, Chesterfield, DeepVerge, Genedrive, Genflow, HFI, Lexington, Ncondezi, Renalytix, Union Jack
It is clear that most stock suspensions on the London market are unnecessary and usually the result of an over zealous regulator enjoying providing private investors with a deep hole in their pocket, and draining the stock market of liquidity. Happily, in the case of All Active (AAA) the company has got on with the job since the suspension last Spring. AAA has agreed non-binding heads of terms for the Sentiance Acquisition and is currently negotiating a binding sale and purchase agreement. The acquisition should be completed before the end of April 2022. To help liquidity, an over the counter market will commence shortly, initially through Oberon Investments (OBE).
Given how central the liver is to health, it can be said that the latest news from Genflow (GENF) could be lead to a significant breakthrough on a human level and for shareholders. The company said it has commenced a scientific research collaboration with the University of Rochester's Aging Research Center. This collaboration will initially research the potential of Sirtuin-6 in reversing the aging process in liver tissue. This is a key milestone for GENF in that the initial premise of the company on listing earlier this year was to slow ageing, rather than reverse it, promising game changing prospects in the medical area.
Another potential game changer would be the prospect of producing Hydrogen from renewable sources – to make it truly green. This is what we have been treated to at Hydrogen Future Industries (HFI), as it announced the incorporation of HFI Energy Systems Limited, which has been formed to develop proprietary wind and water-based hydrogen production systems, incorporating hydrogen compression and storage. To this end Timothy Blake, a motorsport and turbine development specialist, has been appointed Chief Executive Officer of HESL to lead this development.
Another day and more news regarding DeepVerge (DVRG) as Abingdon Health (ABDX), a developer and manufacturer of rapid tests, said it has signed a Memorandum of Understanding with DeepVerge leading to a commercial agreement for development and manufacture of a range of lateral flow tests for DeepVerge's Modern Water and Life Science divisions.
Lexington Gold (LEX), the gold exploration and development company has received initial assay results with respect to Loflin further to the Company's recently completed 5,000m reverse circulation drilling programme. The assay results received relate to 8 of the 18 RC drill holes from the campaign at Loflin, namely 6 holes from Loflin South and 2 holes from the north-eastern extension of the main Loflin deposit.
Capital Metals (CMET), a natural resources company focused on the development of the Eastern Minerals Project located in the Eastern Province in Sri Lanka, announced the issue of an additional exploration license to further extend the Eastern Minerals Project 12 km to the north, including the Oluvil Port. The EL contains areas prospective for further mineral sands resources, which have been identified for follow up drilling later this year.
Renalytix (RENX) announced that the proprietary Renalytix Accelerating Precision medicine In Diabetes (RAPID) biorepository is on track to exceed 4,000 unique patient biospecimens with matching, deidentified electronic health record data in 2022 through the company's real world evidence program.
ANGLE (AGL), a liquid biopsy company, said that the University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute, Baltimore, Maryland, USA, has published results of work undertaken in preclinical models of triple-negative breast cance, showing that isolation of live circulating tumour cells from a simple blood draw, using the Parsortix® system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth.
Aquis Exchange (AQX), the exchange services group, announce its audited results for the year ended 31 December 2021. Revenue up 42% to £16.2 million (FY20: £11.4 million). Pre-tax profit up 540% to £3.2 million (FY20: £0.5 million). Profit after tax up 330% to £4.3 million (FY20: £1.0 million). One wonders whether all of these wonderful metrics are the result of a Niagara of liquidity on the Aquis market, or merely fees from the companies listed? As an ironic gesture Aquis is listing on its on exchange, so one presumes it will get an idea of the lay of the land in terms of liquidity.
Condor Gold (CNR) announced its audited results for the year ended 31 December 2021. Earlier this month the company announced that all assay results had been received for 8.004m infill drilling at the La Mestiza open pit at the La India Project.
Chesterfield Resources (CHF) announced the sign-off and publication of its NI 43-101 technical report on its Adeline project in Labrador, Canada. The company said the report is a key component of the company's application for a secondary listing on the TSX-V exchange in Canada.
Ncondezi Energy (NCCL) provides an update on the integrated Ncondezi 300MW power project in Tete, Mozambique and the working capital facility term loan with Seritza Limited. The company said it continues to work closely with its strategic partner, CMEC to identify a solution to move the Project forward, including engagement with potential private project financiers in China and elsewhere in the world who are not restricted by the Chinese Government's position.
Atlantic Lithium (ALL), the African- focussed lithium exploration and development company announced the appointment of Lennard Alexander Kolff Van Oosterwijk to the Board of Directors and also as the Company's Interim Chief Executive Officer.
Union Jack Oil (UJO) a UK focused onshore hydrocarbon company, provided an update on the Gaffney Cline report in respect of the Wressle hydrocarbon development. The company said the expanded Gaffney Cline report will assist in highlighting the true upside potential of this economically attractive conventional hydrocarbon development.
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announced unaudited interim results for the six months to 31 December 2021. The company said it has achieved some key milestones in this period, namely the CE marking of our Genedrive® POC COVID-19 test, which was closely followed by a number of distribution agreements with key territories. Losses for 2021 at £2.8m were £100k less than 2020.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.